KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Share-based Compensation (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Share-based Compensation for 11 consecutive years, with $18.1 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 17.64% to $18.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $72.5 million through Dec 2025, down 16.25% year-over-year, with the annual reading at $72.5 million for FY2025, 16.25% down from the prior year.
  • Share-based Compensation hit $18.1 million in Q4 2025 for CRISPR Therapeutics AG, up from $16.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $28.3 million in Q2 2021 to a low of $16.6 million in Q3 2025.
  • Historically, Share-based Compensation has averaged $22.0 million across 5 years, with a median of $21.9 million in 2023.
  • Biggest five-year swings in Share-based Compensation: surged 80.49% in 2021 and later decreased 25.62% in 2025.
  • Year by year, Share-based Compensation stood at $25.8 million in 2021, then decreased by 11.5% to $22.8 million in 2022, then dropped by 19.23% to $18.4 million in 2023, then rose by 19.15% to $21.9 million in 2024, then dropped by 17.64% to $18.1 million in 2025.
  • Business Quant data shows Share-based Compensation for CRSP at $18.1 million in Q4 2025, $16.6 million in Q3 2025, and $17.6 million in Q2 2025.